查看新闻
HELIXMITH





Helixmith

Flagship product:Engensis (VM202)




Engensis is aplasmid DNAdesigned to simultaneouslyexpress two isoforms of hepatocyte growth factors (HGF), a protein well known to induce 1) new microvasculatureformation, 2) nerve cell regeneration, 3) ameliorationof atrophic condition,and 4) suppression of pain-related factors.


Based on its excellentsafety and efficacy profile observed through multiple clinical studies, Engensisclinical programs have advanced in the US as follows:


ŸDiabeticperipheral neuropathy (DPN):

USphase III trial on-going, 25 sites and 500+ subjects enrolled, expected tocomplete and announce results in 2019

ŸDiabeticfoot ulcer (DFU):

US phase IIItrial on-going, 28 sites and 300+ subjects planned

ŸAmyotrophiclateral sclerosis (ALS):

Positivetrends on efficacy and safety observed from phase I, US phase II trial plannedto start in 2019


Recognizing VM202s potential, the US FDA granted RMAT (Regenerative MedicineAdvanced Therapy) designation to VM202’s DPN program in 2018, Fasttrack for VM202’s ALS program in 2016.Phase III results for DPN isexpected to be announced in 2019.


Ceresmith


Ceresmithaims to developinnovative healthcare products from plant sources and has two-tier approach indeveloping safe and

effective therapeutics.


Programs

Name

Target disease

Drug

PG201

Osteoarthritis

HX203

Parkinson’s  disease

HX204

Inflammatory bowel disease (IBD)

HX205

Intractable  diabetic

Old  Rx

HX301

Menopausal syndrome

HX302

Depression

Functional

Food

PG102

Improve hypersensitivity reaction

PG102P

Improve  skin pruritus

PG102C

Improve atopy skin dryness

HX106

Improve  memory

HX110

Improve respiratory health

HX112

Improve  menopausal women health



CeresmithContact information

Phytotherapeutics team

Email: zkseong@helixmith.com